THE WOODLANDS, Texas,
Jan. 9, 2016 /PRNewswire/
-- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced
today the commencement of dosing in a Phase 1 clinical trial of
LX2761, an orally-delivered small molecule compound for the
potential treatment of diabetes. LX2761 is an internally
generated compound and is designed to inhibit SGLT1 locally in the
gastrointestinal tract without any significant inhibition of SGLT2
in the kidney.
"Building on science relating to the importance of the
gastrointestinal tract in diabetes and Lexicon's work around the
SGLT1 target, LX2761 provides an approach to glycemic control that
is focused on local action in the GI tract with minimal systemic
absorption," said Praveen Tyle,
Ph.D., Lexicon's executive vice president of research and
development. "LX2761 is a potent, locally-acting SGLT1
inhibitor that may help patients achieve greater glycemic control
without the significantly-elevated urinary glucose excretion that
characterizes inhibitors of SGLT2."
In preclinical studies, LX2761 delayed and reduced intestinal
glucose absorption and reduced postprandial glucose, the level of
blood glucose after a meal, while increasing plasma levels of
GLP-1, consistent with inhibition of intestinal SGLT1. In
addition, LX2761 was minimally absorbed into the systemic
circulation, resulting in little effect on urinary glucose
excretion, indicating that LX2761 was restricted to the
gastrointestinal tract. The initial Phase 1 clinical trial of
LX2761 is planned as a double-blind, randomized,
placebo-controlled, ascending single dose study in both healthy
volunteers and people with type 2 diabetes. The study is
designed to evaluate the safety and tolerability of LX2761.
Lexicon has granted Sanofi certain rights of first negotiation with
respect to the future development and commercialization of
LX2761.
About Lexicon
Lexicon is a fully integrated biopharmaceutical company that is
applying a unique approach to gene science based on Nobel
Prize-winning technology to discover and develop precise medicines
for patients with serious, chronic conditions. Through its
Genome5000™ program, Lexicon scientists have studied the role and
function of nearly 5,000 genes over the last 20 years and have
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to safely and effectively
treat disease. Lexicon has a pipeline of promising drug candidates
in clinical and pre-clinical development in oncology, diabetes and
metabolism, and neuropathic pain. For additional information please
visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements,"
including statements relating to Lexicon's and its licensees'
clinical development of and regulatory filings for LX2761 and the
results and projected timing of clinical trials and the potential
therapeutic and commercial potential of LX2761. In addition, this
press release also contains forward-looking statements relating to
Lexicon's growth and future operating results, discovery and
development of products, strategic alliances and intellectual
property, as well as other matters that are not historical facts or
information. All forward-looking statements are based on
management's current assumptions and expectations and involve
risks, uncertainties and other important factors, specifically
including the risk that clinical studies of LX2761 may be halted,
delayed or otherwise not demonstrate safety or efficacy, the risk
that the FDA and other regulatory authorities may not grant
regulatory approval of LX2761 in accordance with Lexicon's
currently anticipated timelines or at all, and the risk that such
regulatory approvals, if granted, may have significant limitations
on the approved use of LX2761. As a result, LX2761 may never be
successfully commercialized. Other risks include Lexicon's ability
to meet its capital requirements, successfully conduct preclinical
and clinical development and obtain necessary regulatory approvals
of its other potential drug candidates, achieve its operational
objectives, obtain patent protection for its discoveries and
establish strategic alliances, as well as additional factors
relating to manufacturing, intellectual property rights, and the
therapeutic or commercial value of its drug candidates. Any of
these risks, uncertainties and other factors may cause Lexicon's
actual results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
"Risk Factors" in Lexicon's annual report on Form 10-K for the year
ended December 31, 2015, as filed
with the Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lexicon-begins-phase-1-clinical-trial-of-locally-acting-sglt1-inhibitor-lx2761-for-potential-treatment-of-diabetes-300387526.html
SOURCE Lexicon Pharmaceuticals, Inc.